APLS 2017 Annual Report

Directors Cedric Francois, M.D., Ph.D. Apellis Pharmaceuticals, Inc. Gerald Chan, D.Sc. Morningside A. Sinclair Dunlop Epidarex Capital Alec Machiels Pegasus Capital Advisors Stephanie Monaghan O’Brien Morningside Executive Officers Cedric Francois, M.D., Ph.D. President & Chief Executive Officer Pascal Deschatelets, Ph.D. Chief Operating Officer Steven Axon Chief Business Officer Federico Grossi, M.D., Ph.D. Executive VP of Clinical Development & Medical Affairs Nicole Perry Vice President of Finance Lukas Scheibler, Ph.D. Executive VP of Research & Development Timothy Sullivan Chief Financial Officer & Treasurer David Watson General Counsel & VP of Corporate Development Stock Listing Our common stock is traded on Nasdaq Global Select Market under the symbol “APLS”. Investor Information You may obtain a copy of any of the exhibits to our Annual Report on Form 10-K free of charge. These documents are available on our website at www.apellis.com or by contacting our Investor Relations. Requests for information about Apellis Pharmaceuticals, Inc. should be directed to: Investor Relations W2Opure Alex Kane investors@apellis.com Annual Meeting The annual meeting of stockholders will be held at the time and location stated below. Monday, June 4, 2018 11:00 a.m. ET Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 Corporate Counsel Wilmer Cutler Pickering Hale and Dorr LLP Boston, Massachusetts Independent Registered Public Accounting Firm Ernst & Young LLP Louisville, Kentucky Transfer Agent and Registrar The transfer agent is responsible, among other things, for handling stockholder questions regarding lost stock certificates, address changes, including duplicate mailings and changes in ownership or name in which shares are held. These requests may be directed to the transfer agent at the following addresses: American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn, NY 11219 www.amstock.com